GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Wiley  (4)
  • Huang, Xin  (4)
Materialart
Verlag/Herausgeber
  • Wiley  (4)
Sprache
Erscheinungszeitraum
Fachgebiete(RVK)
  • 1
    In: British Journal of Haematology, Wiley, Vol. 193, No. 5 ( 2021-06), p. 928-940
    Kurzfassung: Sophisticated cross‐talk between bone marrow mesenchymal stromal cells (BM MSCs) and haematopoietic/leukaemic stem cells in patients with myelodysplastic syndromes (MDS) and myeloid leukaemia have been emphasized in previous reports. However, mesenchymal elements in patients with chronic myelomonocytic leukaemia (CMML) were poorly investigated. By utilizing a parallel RNA‐sequencing method, we investigated the transcriptional profile and functional defects of primary BM MSCs from patients with CMML for the first time. Within a 24‐patient cohort, transcriptional and functional analysis reveals a prominent enrichment of WNT/β‐catenin signalling and multiple biology processes. Deregulated expression of WNT/β‐catnin factors CTNNB1 , CMYC , LEF1 , and FRZB is associated with impaired proliferation, senescence phenotype, and abnormal secretion in CMML MSCs. The impaired ability to support healthy CD34 + haematopoietic stem and progenitor cells (HSPCs) correlates with activation of WNT/β‐catenin signalling in CMML MSCs. Furthermore, we observed an association between WNT/β‐catenin factors and treatment response to hypomethylating agents (HMAs) in a cohort of patients with MDS/myeloproliferative neoplasms (MPNs). Taken together, our study provides evidence for transcriptional and functional abnormalities in CMML MSCs, and suggests potential prognostic value of evaluating WNT/β‐catenin signalling in patients with CMML.
    Materialart: Online-Ressource
    ISSN: 0007-1048 , 1365-2141
    URL: Issue
    RVK:
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 1475751-5
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    In: Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 16, No. 2 ( 2020-04)
    Kurzfassung: Immune suppression based on alternative regulation of immune checkpoint proteins, for example, programmed cell death receptor‐1 (PD‐1) and cytotoxic T lymphocyte–associated molecule‐4 (CTLA‐4), which results in T‐cell exhaustion, contributes to cancer development and progression. In this study, we sought to characterize the distribution of CTLA‐4 and T‐cell lymphocyte activation gene‐3 (LAG‐3) expression on exhausted T cells in different T‐cell subsets from patients with acute myeloid leukemia (AML). Methods The coexpression of CTLA‐4 and LAG‐3 on exhausted CD244 + and CD57 + T cells from the CD3 + , CD4 + , and CD8 + T‐cell subsets in peripheral blood from 12 patients with newly diagnosed AML was analyzed by multicolor flow cytometry assay. Results A significantly higher percentage of CTLA‐4 + CD3 + , CD4 + and CD8 + T cells was found in patients with AML. In addition, higher numbers of both CTLA‐4 + CD244+ and CTLA‐4 + CD57 + CD3 + T cells were detected. Interestingly, the increased CTLA‐4 + CD244 + T cells were predominantly CD4 + T cells. In contrast, the increased CTLA‐4 + CD57 + T cells primarily consisted of the CD8 + T‐cell subset. A high proportion of LAG‐3 + T cells was found in only a few cases with AML; however, a significantly higher proportion of coexpression of CTLA‐4 and LAG‐3 in the CD3 + and CD8 + T‐cell subsets was detected. Conclusion We for the first time observed higher CTLA‐4 + CD244 + CD4 + , CTLA‐4 + CD57 + CD8 + , CTLA‐4 + LAG‐3 + CD3 + and CTLA‐4 + LAG‐3 + CD8 + T cells in patients with AML, whereas the upregulated expression of LAG‐3 on T cells was only found in a subset of the cases. These data may provide further information by complementing the heterogeneity of immune checkpoints expression in AML.
    Materialart: Online-Ressource
    ISSN: 1743-7555 , 1743-7563
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2020
    ZDB Id: 2187409-8
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: Clinical Transplantation, Wiley, Vol. 29, No. 6 ( 2015-06), p. 547-554
    Kurzfassung: Cutaneous damage is one of the characterized manifestations in chronic graft‐versus‐host disease ( cGVHD ). When local effective immunity in the skin is altered to a dysimmune reaction, cutaneous injuries occur. Toll‐like receptor 4 signaling is regarded as a central mediator of inflammation and organ injury. In this study, we found that TLR 4 m RNA in peripheral blood from patients with cutaneous c GVHD was markedly increased compared with that from non‐ GVHD patients and healthy controls. In addition, NF ‐κ B expression, TLR 4 downstream signaling, and TLR 4‐mediated cytokines, including IL ‐6 and ICAM ‐1, were upregulated. Moreover, ICAM ‐1 was widely distributed in skin biopsies from patients with cutaneous c GVHD . We also found that LPS induced TLR 4‐mediated NF ‐κB activation and IL ‐6 and ICAM ‐1 secretion in human fibroblasts in vitro . Thus, TLR 4, NF ‐κB, IL ‐6, and ICAM ‐1 contribute to the inflammatory response that occurs in cutaneous c GVHD , indicating the TLR 4 pathway may be a novel target for cutaneous c GVHD therapy.
    Materialart: Online-Ressource
    ISSN: 0902-0063 , 1399-0012
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2015
    ZDB Id: 2739458-X
    ZDB Id: 2004801-4
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Clinical and Translational Science, Wiley
    Kurzfassung: Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax(Vene) with Hypomethylating agents (HMAs). The study's findings show promise: the HMAs plus Vene group (n=13, 53.8%) demonstrated superior overall response rates compared to the HMA mono group (n=19, 31.6%) and HMA plus arsenic trioxide (ATO) group (n=9, 22.2%) by the 2nd cycle, and notably higher response rates (53.8% vs. 15.7%, P = 0.04) compared to the HMA mono group after four cycles. Over a median follow‐up of 14.7 months, the HMAs plus Vene group exhibited significantly lower cumulative mortality (23.1%) compared to the other two groups (P = 0.003 and P = 0.008, respectively). Furthermore, this group displayed extended overall survival (OS) compared to the others. The study also delved into the molecular mechanisms, revealing significant BCL2 mRNA overexpression in CMML patients. These findings suggest the potential for HMAs combined with Vene therapy in CMML but emphasize the necessity for further prospective studies to determine its precise role in managing CMML.
    Materialart: Online-Ressource
    ISSN: 1752-8054 , 1752-8062
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2023
    ZDB Id: 2433157-0
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...